Analysis of results heterogeneity of NOACs vs warfarin.

Given are the main results (including all dosages or the dose with most pronounced efficacy result)* and grouping by regimen (BID or QD) are displayed. BID, twice-daily dosing; FEM, fixed-effects meta-analysis; NOACs, novel oral anticoagulants; QD, once-daily dosing. Note. Bold font marks nearly absence of heterogeneity, i.e., generation of a common estimate is justified. *Dose with most pronounced efficacy result: dabigatran 150 mg BID, apixaban 5/2.5 mg BID, rivaroxaban 20/15 mg QD, and edoxaban 60/30 mg QD.